Replies to post #525 on $Bob's and Jbem's Bitchin' Bios

[RealGenius]

Adherex Technologies
ADHXF OTC
AHX Toronto Stock Exchange
$0.67
MarCap: $23M
O/S: 29M

Study ACCL0431, A Randomized Phase III Study of Sodium Thiosulfate for the Prevention of Cisplatin-Induced Ototoxicity in Children.

Has results. Abstract submitted to ASCO for presentation of full data set with stats.

Data from Clinical Trials .gov;
Treatment group : Hearing loss 14 of 49
Control group : Hearing loss 31 of 56

ClinicalTrials.gov
Study # ACCL0431

Investor presentation from Jan. 2014.
http://adherex.com/wp-content/uploads/2014/02/Adherex-Corporate-Presentation-January-2014.pdf